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Introduction
A protective effect of mupirocin has been seen among
surgical, nonsurgical and dialysis patients. Our aim is to
summarize evidence for mupirocin decolonization for
prevention of S. aureus infections in non-surgical
healthcare settings.
Objectives
To identify the optimal setting and patient population to
implement mupirocin decolonization for prevention of
S. aureus infections using meta-analytic methods.
Methods
We conducted systematic searches in PubMed, Cochrane
Library Databases, Scopus, Web of Science, and Clinical-
Trials.gov to identify papers published until 2013 on
effectiveness of mupirocin in healthcare settings. Two
investigators independently abstracted data with a pilot-
tested form. Risk of bias was assessed using the Cochrane
tool. The crude odds ratios were pooled (cpOR) using a
random-effects model. Heterogeneity was evaluated
using the Woolf’s test for homogeneity and I2 statistics.
Results
Of the 12,644 studies identified, 8 randomized controlled
trials and 19 quasi-experimental studies met the study
inclusion criteria. Mupirocin was observed to reduce the
odds of S. aureus infections by 70% (cpOR=0.30, 95% CI
0.23, 0.39) and 60% (cpOR=0.40, 95% CI 0.27, 0.62) in
both dialysis and non-dialysis settings, respectively.
Nevertheless, there was highly significant (p=0.0009) and
moderate heterogeneity (I2=46%) among studies. Studies
were homogeneous (p>0.1) when stratified analyses were
performed by specific clinical settings. Among the 6 stu-
dies that took place in adult intensive care units (ICUs),
mupirocin decolonization was associated with a 56%
reduction in the odds of S. aureus infection (cpOR=0.44,
95% CI 0.26, 0.73). There was also a protective effect of
mupirocin against S. aureus exit site infections among
patients undergoing peritoneal dialysis (cpOR=0.23, 95%
CI 0.15, 0.36) and against bacteremia among hemodialysis
patients (cpOR=0.15, 95%CI 0.06, 0.36).
Conclusion
Mupirocin decolonization is protective against S. aureus
infections among both dialysis and adult ICU patient
populations. Future studies should target other patient
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